Protein Dynamic Solutions, Inc.
Wilmington, DE · Founded 2018 · CIK 0001780775 · Biotech · Private
Software platform for evaluating critical quality attributes (CQAs) in biopharmaceutical drug development
pdsbio.com →- Grants
- $900K
- 2 awards
- Sector median: 1
- Raised
- $3.4M
- 3 Form D · Nov 2025
- 11 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 24
- 6 granted · 18 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2014201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | National Science Foundation · Phase I · SBIR Phase I: Novel, Accurate and Reproducible Platform for the Developability Assessment of Protein Therapeutics | $150,000 | |
| Federal grant | National Science Foundation · Phase II · SBIR Phase II: Novel, Accurate and Reproducible Platform for the Developability Assessment of Protein Therapeutics | $750,000 | |
| Private capital raised | Form D · SEC | $1,000,000 | |
| Private capital raised | Form D · SEC | $610,000 | |
| Private capital raised | Form D · SEC | $1,772,369 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2327 | Landos Biopharma | — | $60M |
| 2328 | RESVITA BIO, INC. | — | — |
| 2329 | CALLENTIS CONSULTING GROUP LLC | — | — |
| 2330 | Protein Dynamic Solutions, Inc. | — | $3.4M |
| 2331 | GlycoEra | — | — |
| 2332 | Secura Bio, Inc. | — | $50M |
| 2333 | NEMAGEN DISCOVERIES INC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Eduardo Canto RepettiDirector
- Jose CasellasExecutive Officer
- Anttoine De MarsilyDirector
- Ricardo EliasDirector
- William Lockwood BenetDirector · Executive Officer
- Belinda PastranaDirector · Executive Officer
- Emilio RiveraDirector
- Joaquin VisoDirector
Patents
- Rapid Deamidation Screeningapplication
- System And Method For Determining Deamidation And Immunogenicity Of Polypeptidesapplication
- Method And System For Spectral Data Analysisapplication
- Method And System For Analyst Of Crystals And Crystallizationapplication
- Sampling Array Devices And System For Spectral Analysisapplication
- Method And System For Analyst Of Crystals And Crystallizationgranted
- Method And System For Spectral Data Analysisgranted
- Sampling Array Devices And System For Spectral Analysisgranted
- Method And System For Analyst Of Crystals And Crystallizationgranted
- System And Method For Determining Deamidation And Immunogenicity Of Polypeptidesapplication
- Sampling Array Devices And System For Spectral Analysisgranted
- Method And System For Spectral Data Analysisgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.